today reported unaudited consolidated economic results for the 3rd quarter ended September 30, 2011. Additionally, AMAG announced leadership changes, like the departure of the company’s president and ceo, Brian J.G. Pereira, MD, and the execution of a broad restructuring intend to reduce operating expenses. As of 30 September, 2011, the company’s cash, money equivalents and investments totaled approximately $251 million. Pereira offers resigned from his placement as president, CEO and a director of the ongoing company, effective immediately. Dr. Pereira will remain a key strategic advisor to the business on certain matters, including the ongoing advancement and regulatory work linked to its broad stage III program for patients with iron deficiency anemia .The price of response to these annual follow-ups was more than 99 percent in all three groups. For reported deaths due to colorectal cancer during the initial 15 years of the analysis, medical records and loss of life certificates were reviewed and adjudicated by a deaths-review committee whose associates were unaware of the study-group assignments. The dedication of all other causes of loss of life was based on coded death certificates, that have been coded by the analysis staff during the first 18 years and were subsequently attained from the National Death Index . Death certificates were coded according to the 8th , 9th, and 10th revisions of the International Classification of Diseases, according to the date of death.